Alopecia prevention during chemotherapy: from the benchmark to real clinical practice. A prospective study

Cover Page

Cite item

Full Text

Abstract

Background. Alopecia is one of the main side effects of anticancer chemotherapy and has a significant impact on patients’ appearance, quality of life, social adaptation and mental health of cancer patients. Estimated number of new cancer diagnosis increases annually alongside with the proportion of patients receiving chemotherapy. That means an annual increase in the global burden of chemo-induced alopecia and associated negative consequences. The development of various methods for the prevention of alopecia in cancer patients has continued for decades. However, convincing data have been obtained only for the scalp hypothermia method. In this point, the Paxman company’s cooling systems (UK) – the Orbis and Orbis II devices – have been most widely studied. Despite the fact that Orbis devices were approved in Russia more than 10 years ago, since then just a small amount of real clinical practice has been accumulated and questions regarding the effectiveness of scalp hypothermia in patients with variable cancers still remain open.

Aim. Analysis of local clinical practice with scalp hypothermia via the Orbis II device for the prevention of alopecia in patients receiving various chemotherapy regimens.

Materials and methods. An open, prospective, single-center study included patients with various cancer types who were indicated for chemotherapy. Orbis II device was used for prophylactic hypothermia. The severity of alopecia was assessed according to the CTCAE version 5.0 at baseline and during anticancer therapy.

Results. From June 2022 to May 2023, scalp cooling procedures were performed in 51 patients, of them 78% of all procedures were performed in female cancers: breast tumors – 109 (52.2%) procedures, ovarian cancer– 33 (15.8%), and cervix cancer – 22 (10.5%). The effectiveness of scalp hypothermia in preventing of severe alopecia was 73%.

Conclusion. Scalp cooling can be considered as an effective method for the prevention of chemotherapy induced alopecia. Further studies are needed to assess larger patient populations to identify favorable and negative factors that affect potency of the hypothermia.

About the authors

Marina A. Lyadova

Moscow State Budgetary Healthcare Institution “Moscow City Oncological Hospital No. 1 of the Moscow Department of Healthcare”; Novokuznetsk State Institute for Further Training of Physicians – branch of the Russian Medical Academy of Continuous Professional Education

Author for correspondence.
Email: dr.lyadova@gmail.com
ORCID iD: 0000-0002-9558-5579
SPIN-code: 8220-2854

Cand. Sci. (Med.)

Russian Federation, Moscow; Novokuznetsk

Tatiana A. Nersesova

Moscow State Budgetary Healthcare Institution “Moscow City Oncological Hospital No. 1 of the Moscow Department of Healthcare”

Email: dr.lyadova@gmail.com
ORCID iD: 0000-0002-7853-0349

oncologist

Russian Federation, Moscow

Anastasia A. Zhuravleva

Moscow State Budgetary Healthcare Institution “Moscow City Oncological Hospital No. 1 of the Moscow Department of Healthcare”

Email: dr.lyadova@gmail.com
ORCID iD: 0009-0009-8951-9792

Treatment Nurse

Russian Federation, Moscow

Denis S. Fedorinov

Moscow State Budgetary Healthcare Institution “Moscow City Oncological Hospital No. 1 of the Moscow Department of Healthcare”; Russian Medical Academy of Continuous Professional Education

Email: dr.lyadova@gmail.com
ORCID iD: 0000-0001-5516-7367
SPIN-code: 1079-8460

oncologist

Russian Federation, Moscow; Moscow

Anna A. Dudnik

Moscow State Budgetary Healthcare Institution “Moscow City Oncological Hospital No. 1 of the Moscow Department of Healthcare”

Email: dr.lyadova@gmail.com
ORCID iD: 0009-0004-7006-7873

Senior Nurse

Russian Federation, Moscow

Elena A. Denisova

Moscow State Budgetary Healthcare Institution “Moscow City Oncological Hospital No. 1 of the Moscow Department of Healthcare”

Email: dr.lyadova@gmail.com
ORCID iD: 0009-0006-9776-9124

Senior Nurse

Russian Federation, Moscow

Margarita V. Nosova

Moscow State Budgetary Healthcare Institution “Moscow City Oncological Hospital No. 1 of the Moscow Department of Healthcare”

Email: dr.lyadova@gmail.com
ORCID iD: 0009-0003-0622-2528

oncologist

Russian Federation, Moscow

Olesya A. Pardabekova

Moscow State Budgetary Healthcare Institution “Moscow City Oncological Hospital No. 1 of the Moscow Department of Healthcare”

Email: dr.lyadova@gmail.com
ORCID iD: 0000-0001-5610-4595

oncologist

Russian Federation, Moscow

Kristina N. Lisitsyna

Moscow State Budgetary Healthcare Institution “Moscow City Oncological Hospital No. 1 of the Moscow Department of Healthcare”

Email: dr.lyadova@gmail.com
ORCID iD: 0009-0002-6817-4907

oncologist

Russian Federation, Moscow

Veronika M. Tuleiko

Moscow State Budgetary Healthcare Institution “Moscow City Oncological Hospital No. 1 of the Moscow Department of Healthcare”

Email: dr.lyadova@gmail.com
ORCID iD: 0009-0001-4913-7601

oncologist

Russian Federation, Moscow

Olesya A. Bikmurzina

Moscow State Budgetary Healthcare Institution “Moscow City Oncological Hospital No. 1 of the Moscow Department of Healthcare”

Email: dr.lyadova@gmail.com
ORCID iD: 0009-0004-6671-9234

Hospital Nurse

Russian Federation, Moscow

References

  1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. doi: 10.3322/caac.21660
  2. Wilson BE, Jacob S, Yap ML, et al. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. Lancet Oncol. 2019;20(6):769-80. doi: 10.1016/S1470-2045(19)30163-9
  3. Каприн А.Д., Старинский В. В., Шахзадова А. О. Состояние онкологической помощи населению России в 2021 г. М.: МНИОИ им. П. А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022 [Kaprin AD, Starinskii VV, Shakhzadova AO. Sostoianie onkologicheskoi pomoshchi naseleniiu Rossii v 2021 g. Moscow: MNIOI im. P. A. Gertsena – filial FGBU «NMITs radiologii» Minzdrava Rossii, 2022 (in Russian)].
  4. Станоевич И.В., Хвостовой В. В., Тишина Е. И., и др. Алопеция в онкологии: практическое значение фундаментальных исследований. Сибирский онкологический журнал. 2023;22(1):128-40 [Stanoevich IV, Khvostovoy VV, Tishina EI, et al. Alopecia in oncology: the practical significance of fundamental research. Siberian Journal of Oncology. 2023;22(1):128-40 (in Russian)]. doi: 10.21294/1814-4861-2023-22-1–128-140
  5. Choi EK, Kim I-R, Chang O, et al. Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients. Psychooncology. 2014;23(10):1103-10. doi: 10.1002/pon.3531
  6. Boland V, Brady AM, Drury A. The physical, psychological and social experiences of alopecia among women receiving chemotherapy: an integrative literature review. Eur J Oncol Nurs. 2020;49:101840. doi: 10.1016/j.ejon.2020.101840
  7. Freites-Martinez A, Chan D, Sibaud V, et al. Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia. JAMA Dermatol. 2019;155(6):724-8. doi: 10.1001/jamadermatol.2018.5071
  8. Красильникова Н.Е., Петкау В. В., Демидов С. М., и др. Наиболее значимые для пациентов побочные эффекты химиотерапии. В: Актуальные вопросы современной медицинской науки и здравоохранения: материалы VII Междунар. науч.-практ. конф. молодых ученых и студентов. Екатеринбург: ФГБОУ ВО «УГМУ» МЗ РФ, 2022; с. 2631-6 [Krasil’nikova NE, Petkau VV, Demidov SM, et al. Naibolee znachimye dlia patsientov pobochnye effekty khimioterapii. In: Aktual’nye voprosy sovremennoi meditsinskoi nauki i zdravookhraneniia: materialy VII Mezhdunar. nauch.-prakt. konf. molodykh uchenykh i studentov. Ekaterinburg: FGBOU VO «UGMU» MZ RF, 2022; s. 2631-6 (in Russian)].
  9. Paterson C, Kozlovskaia M, Turner M, et al. Identifying the supportive care needs of men and women affected by chemotherapy-induced alopecia? A systematic review. J Cancer Surviv. 2021;15(1):14-28. doi: 10.1007/s11764-020-00907-6
  10. Kang D, Kim IR, Choi EK, et al. Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study. Oncologist. 2019;24(3):414-20. doi: 10.1634/theoncologist.2018-0184
  11. Chan J, Adderley H, Alameddine M, et al. Permanent hair loss associated with taxane chemotherapy use in breast cancer: A retrospective survey at two tertiary UK cancer centres. Eur J Cancer Care (Engl). 2021;30(3):e13395. doi: 10.1111/ecc.13395
  12. Paus R, Haslam IS, Sharov AA, Botchkarev VA. Pathobiology of chemotherapy-induced hair loss. Lancet Oncol. 2013;14(2):e50-9. doi: 10.1016/S1470-2045(12)70553-3
  13. Rodriguez R, Machiavelli M, Leone B, et al. Minoxidil (Mx) as a prophylaxis of doxorubicin – induced alopecia. Annals Oncol. 1994;5(8):769-70. doi: 10.1093/oxfordjournals.annonc.a058986
  14. Wikramanayake TC, Haberland NI, Akhundlu A, et al. Prevention and Treatment of Chemotherapy-Induced Alopecia: What Is Available and What Is Coming? Curr Oncol. 2023;30(4):3609-26. doi: 10.3390/curroncol30040275
  15. Wang J, Lu Z, Au JL-S. Protection against chemotherapy-induced alopecia. Pharm Res. 2006;23(11):2505-14. doi: 10.1007/s11095-006-9105-3
  16. Hidalgo M, Rinaldi D, Medina G, et al. A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia. Anticancer Drugs. 1999;10(4):393-5. doi: 10.1097/00001813-199904000-00007
  17. Dunnill CJ, Al-Tameemi W, Collett A, et al. A Clinical and Biological Guide for Understanding Chemotherapy-Induced Alopecia and Its Prevention. Oncologist. 2018;23(1):84-96. doi: 10.1634/theoncologist.2017-0263
  18. Komen MMC, Smorenburg CH, Nortier JWR, et al. Results of scalp cooling during anthracycline containing chemotherapy depend on scalp skin temperature. Breast. 2016;30:105-10. doi: 10.1016/j.breast.2016.09.007
  19. Komen MMC, van den Hurk CJG, Nortier JWR, et al. Prolonging the duration of post-infusion scalp cooling in the prevention of anthracycline-induced alopecia: a randomised trial in patients with breast cancer treated with adjuvant chemotherapy. Supportive Care Cancer. 2019;27(5):1919-25. doi: 10.1007/s00520-018-4432-6
  20. Massey CS. A multicentre study to determine the efficacy and patient acceptability of the Paxman Scalp Cooler to prevent hair loss in patients receiving chemotherapy. Eur J Oncol Nurs. 2004;8(2):121-30. doi: 10.1016/j.ejon.2003.10.006
  21. Vasconcelos I, Wiesske A, Schoenegg W. Scalp cooling successfully prevents alopecia in breast cancer patients undergoing anthracycline/taxane-based chemotherapy. Breast. 2018;40:1-3. doi: 10.1016/j.breast.2018.04.012
  22. Nangia J, Wang T, Osborne C, et al. Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer. JAMA. 2017;317(6):596-605. doi: 10.1001/jama.2016.20939
  23. van den Hurk CJ, Peerbooms M, van de Poll-Franse LV, et al. Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients – results of the Dutch Scalp Cooling Registry. Acta Oncol. 2012;51(4):497-504. doi: 10.3109/0284186X.2012.658966
  24. Gianotti E, Razzini G, Bini M, et al. Scalp Cooling in Daily Clinical Practice for Breast Cancer Patients Undergoing Curative Chemotherapy: A Multicenter Interventional Study. Asia Pac J Oncol Nurs. 2019;6(3):277-82. doi: 10.4103/apjon.apjon_4_19
  25. Bajpai J, Kagwade S, Chandrasekharan A, et al. Randomised controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia. Breast. 2020;49:187-93. doi: 10.1016/j.breast.2019.12.004
  26. Полежаева И.С., Старцева Ж. А., Гольдберг В. Е., Попова Н. О. Опыт применения гипотермии волосистой части кожи головы для профилактики алопеции при проведении химиотерапии. Сибирский онкологический журнал. 2017;16(2):66-70 [Polezhaeva IS, Starceva ZhA, Goldberg VE, Popova NO. Experience of scalp cooling for prevention chemotherapy-induced hair loss. Siberian Journal of Oncology. 2017;16(2):66-70 (in Russian)]. doi: 10.21294/18144861-2017-16-2–66-70
  27. Сафина С.З., Мухамедьярова Г. К., Хайруллин И. И. Опыт применения системы глубокой управляемой гипотермии волосистой части головы для профилактики алопеции в процессе химиотерапии. Поволжский онкологический вестник. 2018;1(33):42-4 [Safina SZ, Mukhamediarova GK, Khayrullin II. Chemotherapy-induced hair loss preventing system approbation Results. Oncology Bulletin of the Volga Region. 2018;1(33):42-4 (in Russian)].
  28. Silva G, Moreira R, Gimenes D, et al. abstract P6-11-06: Efficacy of Scalp Cooling in Preventing Chemotherapy-Induced Alopecia in Breast Cancer Patients: A Retrospective, Comprehensive Review of 330 Cases of Brazil. Cancer Res. 2018;78(Supp. 4):P6-11-06-P6-11-06. doi: 10.1158/1538-7445.SABCS17-P6-11-06
  29. Kurbacher CM, Kurbacher A, Herz S, et al. abstract P6-11-14: Safety and effectiveness of sensor-controlled scalp cooling to prevent alopecia in primary breast cancer patients receiving neoadjuvant or adjuvant epirubicin, taxanes, or both. Cancer Res. 2018;78(Supp. 4):P6-11-14-P6-11-4. doi: 10.1158/1538-7445.SABCS17-P6-11-14
  30. Кузьмина Н.В., Павлова Е. А., Шаржанова Н. А. Опыт применения охлаждения волосистой части головы аппаратом Орбис в период химиотерапии с целью профилактики алопеции. В: Современное состояние диагностики и лечения злокачественных новообразований: материалы Межрегион. науч.-практ. конф., посвящ. 75-летию АУ «РКОД» Минздрава Чувашии. Чебоксары: ЧГУ им. И. Н. Ульянова: РКОД МЗ Чувашской Республики, 2021; с. 296-301 [Kuz’mina NV, Pavlova EA, Sharzhanova NA. Opyt primeneniia okhlazhdeniia volosistoi chasti golovy apparatom Orbis v period khimioterapii s tsel’iu profilaktiki alopetsii. In: Sovremennoe sostoianie diagnostiki i lecheniia zlokachestvennykh novoobrazovanii: materialy Mezhregion. nauch.-prakt. konf., posviashch. 75-letiiu AU «RKOD» Minzdrava Chuvashii. Cheboksary: ChGU im. I. N. Ul’ianova: RKOD MZ Chuvashskoi Respubliki, 2021; s. 296-301 (in Russian)].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. The state of the scalp in the patient before (a) and after (b) three courses of chemotherapy with docetaxel + carboplatin.

Download (220KB)
Indexing metadata
3. Fig. 2. The state of the scalp in the patient before (a) and after (b) twelve courses of chemotherapy with paclitaxel + carboplatin (weekly).

Download (188KB)
Indexing metadata
4. Fig. 3. The state of the scalp in the patient before (a) and after (b) five courses of chemotherapy with cisplatin + gemcitabine.

Download (219KB)
Indexing metadata

Copyright (c) 2023 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies